Intellia Therapeutics, Inc. Forecast, price target & analysts
Intellia Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Intellia Therapeutics, Inc. Classifications & Recommendation:
Intellia Therapeutics, Inc. Price Target
| Target Price | $39.71 |
| Price | $8.20 |
| Potential |
384.25%
register free of charge
|
| Number of Estimates | 24 |
|
24 Analysts have issued a price target Intellia Therapeutics, Inc. 2026 .
The average Intellia Therapeutics, Inc. target price is $39.71.
This is
384.25%
register free of charge
$106.00
1,192.68%
register free of charge
$8.00
2.44%
register free of charge
|
|
| A rating was issued by 28 analysts: 21 Analysts recommend Intellia Therapeutics, Inc. to buy, 6 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Intellia Therapeutics, Inc. stock has an average upside potential 2026 of
384.25%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 57.88 | 49.44 |
| 59.54% | 14.59% | |
| EBITDA Margin | -905.29% | -1,007.88% |
| 35.13% | 11.33% | |
| Net Margin | -925.46% | -967.74% |
| 39.28% | 4.57% |
24 Analysts have issued a sales forecast Intellia Therapeutics, Inc. 2025 . The average Intellia Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Intellia Therapeutics, Inc. EBITDA forecast 2025. The average Intellia Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Intellia Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Intellia Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.25 | -4.69 |
| 3.14% | 10.67% | |
| P/E | negative | |
| EV/Sales | 9.25 |
25 Analysts have issued a Intellia Therapeutics, Inc. forecast for earnings per share. The average Intellia Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Intellia Therapeutics, Inc....
Current Intellia Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wolfe Research |
Locked
➜
Locked
|
Locked | Apr 21 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Apr 21 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Feb 28 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
